Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Market Closed - Toronto S.E.
Other stock markets
 21:00:00 16/07/2024 BST 		5-day change 1st Jan Change
10.32 CAD +2.89% Intraday chart for Bausch Health Companies Inc. +5.20% -2.92%
07-10 Raymond James Initiates Bausch Health at Market Perform Rating MT
06-21 Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich
Bausch Health Companies Inc. Approves Directorate Appointments
RBC Noes Bausch Health Filing For Rehearing in Appellate Court
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform
Bausch Health Shares Fall Following Q1 Results
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
RBC Previews Bausch Health's Q1, Trims Target to US$11
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock
  5. News Bausch Health Companies Inc.
  6. Other languages